Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:ARVN NASDAQ:KALV NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$6.98+4.3%$7.58$5.47▼$11.99$162.24M-0.2388,505 shs43,195 shsARVNArvinas$9.61+3.7%$7.63$5.90▼$29.61$680.59M2.392.26 million shs1.75 million shsKALVKalVista Pharmaceuticals$11.85+0.9%$13.35$7.30▼$17.28$593.65M-0.151.45 million shs1.74 million shsSVRASavara$3.49$3.22$1.89▼$4.30$603.20M0.461.35 million shs724,264 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+4.33%+1.31%-18.93%+6.97%-1.69%ARVNArvinas+3.67%+16.20%+21.65%+21.78%-61.09%KALVKalVista Pharmaceuticals+0.85%-4.44%-16.31%-0.42%+0.08%SVRASavara0.00%-0.85%+2.05%+63.47%-10.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$6.98+4.3%$7.58$5.47▼$11.99$162.24M-0.2388,505 shs43,195 shsARVNArvinas$9.61+3.7%$7.63$5.90▼$29.61$680.59M2.392.26 million shs1.75 million shsKALVKalVista Pharmaceuticals$11.85+0.9%$13.35$7.30▼$17.28$593.65M-0.151.45 million shs1.74 million shsSVRASavara$3.49$3.22$1.89▼$4.30$603.20M0.461.35 million shs724,264 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+4.33%+1.31%-18.93%+6.97%-1.69%ARVNArvinas+3.67%+16.20%+21.65%+21.78%-61.09%KALVKalVista Pharmaceuticals+0.85%-4.44%-16.31%-0.42%+0.08%SVRASavara0.00%-0.85%+2.05%+63.47%-10.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 2.50Moderate Buy$20.33191.31% UpsideARVNArvinas 2.48Hold$16.1868.41% UpsideKALVKalVista Pharmaceuticals 2.90Moderate Buy$26.43123.03% UpsideSVRASavara 2.57Moderate Buy$7.50114.90% UpsideCurrent Analyst Ratings BreakdownLatest ACTU, ARVN, KALV, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025ACTUActuate TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025KALVKalVista PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025ARVNArvinasBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$10.009/23/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/18/2025ARVNArvinasWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $9.009/18/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $10.009/18/2025ARVNArvinasStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$16.00 ➝ $14.009/17/2025ARVNArvinasBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.009/16/2025ARVNArvinasBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 10/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.01 per shareN/AARVNArvinas$372.80M1.89N/AN/A$8.17 per share1.18KALVKalVista Pharmaceuticals$1.43M419.84N/AN/A$0.81 per share14.63SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$27.28MN/A0.00∞N/AN/AN/A-281.83%N/AARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)KALVKalVista Pharmaceuticals-$183.44M-$3.94N/AN/AN/AN/A-195.62%-89.96%12/4/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest ACTU, ARVN, KALV, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025ARVNArvinas-$0.74N/AN/AN/A$29.36 millionN/A9/11/2025Q1 2026KALVKalVista Pharmaceuticals-$0.91-$1.12-$0.21-$1.12$1.97 million$1.43 million8/14/2025Q2 2025ACTUActuate Therapeutics-$0.19-$0.30-$0.11-$0.30N/AN/A8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83-$3.69-$2.86-$0.99$4.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A0.730.73ARVNArvinasN/A5.645.64KALVKalVista PharmaceuticalsN/A5.375.37SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AARVNArvinas95.19%KALVKalVista PharmaceuticalsN/ASVRASavara87.93%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%ARVNArvinas4.73%KALVKalVista Pharmaceuticals4.30%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1023.24 million7.13 millionN/AARVNArvinas42073.42 million69.95 millionOptionableKALVKalVista Pharmaceuticals10050.52 million48.35 millionOptionableSVRASavara20172.84 million163.63 millionOptionableACTU, ARVN, KALV, and SVRA HeadlinesRecent News About These CompaniesSVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 3 at 12:00 PM | globenewswire.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraOctober 3 at 10:50 AM | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRAOctober 3 at 10:00 AM | prnewswire.comSavara Inc. (NASDAQ:SVRA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 3 at 4:15 AM | marketbeat.comSavara present results from Phase 3 IMPALA-2 Molgramostim studyOctober 2 at 11:23 PM | msn.comClass Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact Levi & KorsinskyOctober 2 at 6:22 PM | theglobeandmail.comSavara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune ...October 2 at 6:22 PM | caledonianrecord.comCSVRA NOTICE: Savara Inc. Investors Urged to Contact Kirby McInerney LLP About Securities Fraud LawsuitOctober 2 at 6:00 PM | globenewswire.comSavara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025October 2 at 4:05 PM | businesswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud LawsuitOctober 2 at 2:58 PM | prnewswire.comROSEN, A RANKED AND LEADING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRAOctober 2 at 1:30 PM | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraOctober 2 at 9:46 AM | prnewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 2 at 8:18 AM | prnewswire.comSavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRAOctober 2 at 8:17 AM | prnewswire.comSavara management to meet virtually with Piper SandlerOctober 1 at 9:28 PM | msn.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in ...October 1 at 9:28 PM | caledonianrecord.comCLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRAOctober 1 at 4:07 PM | globenewswire.comSavara Inc. (SVRA) Shareholders Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 1 at 12:00 PM | prnewswire.comNovember 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRAOctober 1 at 8:45 AM | prnewswire.comLost Money on Savara Inc. (SVRA)? Contact Levi & Korsinsky Before November 7, 2025 to Join Class ActionOctober 1 at 6:24 AM | theglobeandmail.comROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRASeptember 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Eli Lilly’s Oral GLP-1 Breakthrough Could Change EverythingBy Chris Markoch | September 18, 2025Intel + NVIDIA: The Unexpected AI Alliance Shaking Wall StreetBy Jeffrey Neal Johnson | September 25, 2025Industrial Tech Crossovers: When Manufacturing Meets InnovationBy Nathan Reiff | September 23, 2025Union Pacific: Laying the Tracks for America's Industrial RenewalBy Jeffrey Neal Johnson | September 7, 2025ACTU, ARVN, KALV, and SVRA Company DescriptionsActuate Therapeutics NASDAQ:ACTU$6.98 +0.29 (+4.33%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$7.02 +0.03 (+0.50%) As of 10/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Arvinas NASDAQ:ARVN$9.61 +0.34 (+3.67%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$9.56 -0.05 (-0.57%) As of 10/3/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.KalVista Pharmaceuticals NASDAQ:KALV$11.85 +0.10 (+0.85%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$12.04 +0.19 (+1.60%) As of 10/3/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Savara NASDAQ:SVRA$3.49 0.00 (0.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.52 +0.03 (+0.86%) As of 10/3/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? A Copper Catalyst: Why Freeport-McMoRan Is Positioned to Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
